| Centralized echocardiogram quality control in a multicenter study of regression of left ventricular hypertrophy in hypertension. | |
| | |
MedLine Citation:
|
PMID: 9797199 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
OBJECTIVE: To test the feasibility and utility of instituting centralized echocardiographic quality control during a multicenter study of regression of left ventricular hypertrophy in hypertension. DESIGN AND METHODS: The LIVE (Left Ventricular Hypertrophy: Indapamide Versus Enalapril) study is an ongoing multicenter, double-blind, controlled study of regression of echocardiographic left ventricular mass index in hypertensive patients with left ventricular hypertrophy (left ventricular mass indexes > 100 g/m2 for women and > 120 g/m2 for men) treated for 1 year with 1.5 mg indapamide sustained-release coated tablets versus 20 mg enalapril. A centralized evaluation committee has validated a prestudy sample echocardiogram from each center, and is now reviewing all videotapes recorded during this study for quality control; final results will be based on a further randomized blinded analysis by this centralized evaluation committee. RESULTS: Since December 1994, 878 patients have been preselected (videoechocardiographic recordings sent for assessment), 645 selected (videoechocardiographic recordings validated), and 576 randomly allocated to treatment. After preliminary quality control, 27% (233) of baseline echocardiograms were rejected by our centralized evaluation committee, and 22% (142) of postinclusion echocardiographic measurements had to be repeated, mainly because they were of poor echogenic quality. Analysis of approved baseline echocardiograms for the first 274 randomly allocated patients with digitized data showed that there was a significant correlation between centralized evaluation committee and investigator calculations of left ventricular mass index (r = 0.76, P < 0.001), with consistently higher values for investigator calculations, independently of level of left ventricular mass index (correlation between difference and mean of investigator and centralized evaluation committee measurements, r = 0.08, P = 0.28). The mean difference was 8 +/- 20 g/m2 (P < 0.001). CONCLUSION: Early results of the LIVE study quality control showed that real-time 'live', centralized echocardiographic reading was not only feasible, but also useful for avoiding unquantifiable echocardiograms and overestimation of left ventricular mass index. Thus, real-time, centralized echocardiographic quality control should be recommended for multicenter studies of regression of left ventricular hypertrophy. |
| | |
Authors:
|
P Gosse; D Guez; P Guéret; O Dubourg; A Beauchet; A de Cordoüe; S Barrandon |
Related Documents
:
|
8473659 - Estimation of right ventricular mass in normal subjects and in patients with primary pu... 11812909 - Left ventricular alterations and end-stage renal disease. 10873609 - Cardiac calcineurin during transition from hypertrophy to heart failure in rats. 11838339 - Right ventricular myocardial diastolic dysfunction in different kinds of cardiac hypert... 11202009 - Experimental aortic stenosis and corresponding left ventricular hypertrophy in sheep. 19723539 - Exploiting cgmp-based therapies for the prevention of left ventricular hypertrophy: no*... 19266249 - The effect of beta-blockers on the diagnostic accuracy of vasodilator pharmacologic spe... 12457149 - Heart failure: recent advances in prevention and treatment. 23628009 - Effect of a new class of compounds of the group of substituted 5r1, 6h2-1,3,4-thiadiazi... |
Publication Detail:
|
Type: Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial |
Journal Detail:
|
Title: Journal of hypertension Volume: 16 ISSN: 0263-6352 ISO Abbreviation: J. Hypertens. Publication Date: 1998 Apr |
Date Detail:
|
Created Date: 1999-01-04 Completed Date: 1999-01-04 Revised Date: 2004-11-17 |
Medline Journal Info:
|
Nlm Unique ID: 8306882 Medline TA: J Hypertens Country: ENGLAND |
Other Details:
|
Languages: eng Pagination: 531-5 Citation Subset: IM |
Affiliation:
|
Groupe hospitalier Saint-André, Bordeaux, France. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Antihypertensive Agents / therapeutic use Double-Blind Method Echocardiography / standards* Enalapril / therapeutic use Female Humans Hypertension / drug therapy, physiopathology* Hypertrophy, Left Ventricular / diagnosis*, drug therapy, physiopathology Indapamide / therapeutic use Male Quality Control |
| Chemical | |
Reg. No./Substance:
|
0/Antihypertensive Agents; 26807-65-8/Indapamide; 75847-73-3/Enalapril |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Prognostic significance of hypertension and albuminuria for early mortality after acute myocardial i...
Next Document: Prothrombin fragment 1+2 is a risk factor for myocardial infarction in treated hypertensive men.